Combining CD39 inhibition with ICD-based vaccines boosts CAR-T cell expansion, persistence, and antitumor efficacy in glioma mouse models, overcoming challenges of antigen loss in conventional CAR-T therapies. The gene discussed is ENTPD1; the disease is central nervous system cancer.